Cancer immunotherapies have changed the landscape of cancer treatment during the past few decades. Among them, immune checkpoint inhibitors, which target PD-1, PD-L1 and CTLA-4, are increasingly used for certain cancers; however, this increased use has resulted in increased reports of immune-related adverse events (irAEs). These irAEs are unique and are different to those of traditional cancer therapies, and typically have a delayed onset and prolonged duration. IrAEs can involve any organ or system. These effects are frequently low grade and are treatable and reversible; however, some adverse effects can be severe and lead to permanent disorders. Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the potential of short-term and long-term complications. Thoughtful management of irAEs is important in optimizing quality of life and long-term outcomes.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sanmamed, M. F. & Chen, L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175, 313–326 (2018).
Hoos, A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235–247 (2016).
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018). One of the first central reviews surveying the irAEs associated with ICIs and their management.
Ramos-Casals, M. et al. Immune-related adverse events induced by cancer immunotherapies. Big data analysis of 13,051 cases (Immunocancer International Registry). Ann. Rheum. Dis. 78, 607–608 (2019).
National Cancer Institute. Common terminology criteria for adverse events (CTCAE). NCI https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (2019).
Xu, C. et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363, k4226 (2018). An elegant systematic review and network meta-analysis providing a complete toxicity profile, toxicity spectrum and a safety ranking of the main ICI drugs (nivolumab, pembrolizumab, ipilimumab, tremelimumab and atezolizumab).
Weber, J. S. et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16, 375–384 (2015).
Yoest, J. M. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets Ther. 6, 73–82 (2017).
Parakh, S., Cebon, J. & Klein, O. Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy. Oncologist 23, 849–851 (2018).
Kanjanapan, Y. et al. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Eur. J. Cancer 107, 1–7 (2019).
Sandigursky, S. & Mor, A. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr. Rheumatol. Rep. 20, 65 (2018).
Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H. & Sharpe, A. H. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 40, 511–523 (2019).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Khoja, L., Day, D., Wei-Wu Chen, T., Siu, L. L. & Hansen, A. R. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann. Oncol. 28, 2377–2385 (2017).
Seidel, J. A., Otsuka, A. & Kabashima, K. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front. Oncol. 8, 86 (2018).
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).
Felis-Giemza, A. & Moots, R. J. Measurement of anti-drug antibodies to biologic drugs. Rheumatology 54, 1941–1943 (2015).
Agrawal, S. et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J. Clin. Pharmacol. 57, 394–400 (2017).
Enrico, D., Paci, A., Chaput, N., Karamouza, E. & Besse, B. Anti-drug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of immune activation? Clin Cancer Res. 26, 787–792 (2020).
Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
Cappelli, L. C. et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin. Arthritis Rheum. 48, 553–557 (2018).
Le Burel, S. et al. Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis. Eur. J. Cancer 82, 34–44 (2017).
Lidar, M. et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun. Rev. 17, 284–289 (2018).
Stamatouli, A. M. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67, 1471–1480 (2018).
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O. III & Shah, A. A. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 69, 1751–1763 (2017).
Pizarro, C. et al. PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab. Res. Rev. 30, 761–766 (2014).
Vaidya, B. et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology 41, 180–183 (2002).
Kartolo, A., Sattar, J., Sahai, V., Baetz, T. & Lakoff, J. M. Predictors of immunotherapy-induced immune-related adverse events. Curr. Oncol. 25, e403–e410 (2018).
Eun, Y. et al. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci. Rep. 9, 14039 (2019).
Kichenadasse, G. et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol. 6, 512–518 (2020).
Richtig, G. et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study. PLoS One 13, e0204729 (2018).
Daste, A. et al. Immune checkpoint inhibitors and elderly people: a review. Eur. J. Cancer 82, 155–166 (2017).
Chiarion Sileni, V. et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J. Exp. Clin. Cancer Res. 33, 30 (2014).
Sury, K., Perazella, M. A. & Shirali, A. C. Cardiorenal complications of immune checkpoint inhibitors. Nat. Rev. Nephrol. 14, 571–588 (2018).
Klocke, K., Sakaguchi, S., Holmdahl, R. & Wing, K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc. Natl Acad. Sci. USA 113, E2383–E2392 (2016).
Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).
Lo, B. et al. CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. Blood 128, 1037–1042 (2016).
Selby, M. J. et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1, 32–42 (2013).
Pico de Coana, Y. et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production. Cancer Immunol. Res. 1, 158–162 (2013).
Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233–1238 (2019).
Knochelmann, H. M. et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell. Mol. Immunol. 15, 458–469 (2018).
Noack, M. & Miossec, P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun. Rev. 13, 668–677 (2014).
von Euw, E. et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7, 35 (2009).
Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).
Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691–10696 (2004).
Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206, 3015–3029 (2009).
Gianchecchi, E. & Fierabracci, A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front. Immunol. 9, 2374 (2018).
Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11, 141–151 (1999).
Okazaki, T. et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477–1483 (2003).
Okazaki, T. et al. Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b−/−Pdcd1−/− mice. J. Exp. Med. 202, 1643–1648 (2005).
Gambichler, T. et al. Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade. Br. J. Dermatol. https://doi.org/10.1111/bjd.18379 (2019).
Laurent, S. et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J. Transl. Med. 11, 108 (2013).
Murakami, N., Borges, T. J., Yamashita, M. & Riella, L. V. Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. Clin. Kidney J. 9, 411–417 (2016).
Kim, S. T. et al. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann. Rheum. Dis. 76, 2061–2064 (2017).
Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
Byrne, E. H. & Fisher, D. E. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 123, 2143–2153 (2017).
Cheng, F. & Loscalzo, J. Autoimmune cardiotoxicity of cancer immunotherapy. Trends Immunol. 38, 77–78 (2017).
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).
Petersone, L. et al. T cell/B cell collaboration and autoimmunity: an intimate relationship. Front. Immunol. 9, 1941 (2018).
Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).
Das, R. et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J. Clin. Invest. 128, 715–720 (2018).
de Moel, E. C. et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol. Res. 7, 6–11 (2019).
Delyon, J., Mateus, C. & Lambert, T. Hemophilia A induced by ipilimumab. N. Engl. J. Med. 365, 1747–1748 (2011).
Min, L., Vaidya, A. & Becker, C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur. J. Endocrinol. 164, 303–307 (2011).
Kanameishi, S. et al. Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. Ann. Oncol. 27, 546–547 (2016).
Kong, Y.-C. M. & Flynn, J. C. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front. Immunol. 5, 206 (2014).
Sadik, C. D., Langan, E. A., Gratz, V., Zillikens, D. & Terheyden, P. Checkpoint inhibition may trigger the rare variant of anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid. Front. Immunol. 10, 1934 (2019).
Ramos-Casals, M. et al. Sicca/Sjogren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR). Clin. Exp. Rheumatol. 37, 114–122 (2019).
Warner, B. M. et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist 24, 1259–1269 (2019).
Cappelli, L. C. et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis. 76, 43–50 (2017).
Makarious, D., Horwood, K. & Coward, J. I. G. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur. J. Cancer 82, 128–136 (2017).
Suzuki, S. et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89, 1127–1134 (2017).
Grabie, N. et al. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116, 2062–2071 (2007).
Zhang, L. et al. Cardiotoxicity of immune checkpoint inhibitors. Curr. Treat. Options Cardiovasc. Med. 21, 32 (2019).
Mahmood, S. S. et al. Myocarditis in patients treated with immune checkpoint inhibitors. J. Am. Coll. Cardiol. 71, 1755–1764 (2018).
Heinzerling, L. et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer 4, 50 (2016).
Zimmer, L. et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 210–225 (2016).
Belum, V. R. et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur. J. Cancer 60, 12–25 (2016).
Voskens, C. J. et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8, e53745 (2013).
Goldinger, S. M. et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin. Cancer Res. 22, 4023–4029 (2016).
Sibaud, V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am. J. Clin. Dermatol. 19, 345–361 (2018).
Weber, J. S., Kahler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691–2697 (2012).
Sosa, A., Lopez Cadena, E., Simon Olive, C., Karachaliou, N. & Rosell, R. Clinical assessment of immune-related adverse events. Ther. Adv. Med. Oncol. 10, 1758835918764628 (2018).
Minkis, K., Garden, B. C., Wu, S., Pulitzer, M. P. & Lacouture, M. E. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J. Am. Acad. Dermatol. 69, e121–e128 (2013).
Liu, X. & Qin, S. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges. Oncologist 24, S3–S10 (2019).
Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5, 95 (2017).
Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl. Compr. Cancer Netw. 17, 255–289 (2019).
Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 36, 1714–1768 (2018). A practical, central position document convened by a multi-disciplinary, multi-organizational panel of experts (from medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, haematology, emergency medicine, nursing, trialist and advocacy) offering guidance on the recommended management of irAEs in patients treated with ICIs.
Girotra, M. et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2, pky021 (2018).
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J. & Fagin, J. A. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21, 371–381 (2014).
Corsello, S. M. et al. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98, 1361–1375 (2013).
Sznol, M. et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat. Rev. 58, 70–76 (2017).
Lu, J., Li, L., Lan, Y., Liang, Y. & Meng, H. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis. Cancer Med. 8, 7503–7515 (2019).
Barroso-Sousa, R. et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 4, 173–182 (2018). A systematic review and meta-analysis analysing the incidence of all-grade hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency and insulin-deficient diabetes mellitus associated with ICIs.
Dillard, T., Yedinak, C. G., Alumkal, J. & Fleseriu, M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13, 29–38 (2010).
Faje, A. T. et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J. Clin. Endocrinol. Metab. 99, 4078–4085 (2014).
Byun, D. J., Wolchok, J. D., Rosenberg, L. M. & Girotra, M. Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13, 195–207 (2017).
Chang, L.-S. et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40, 17–65 (2019).
Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789–1801 (2018).
Naidoo, J. et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol. 35, 709–717 (2017).
Hassel, J. C. et al. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat. Rev. 57, 36–49 (2017).
Delivanis, D. A. et al. Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms. J. Clin. Endocrinol. Metab. 102, 2770–2780 (2017).
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220–2229 (2018).
Geukes Foppen, M. H. et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3, e000278 (2018).
Hughes, M. S. et al. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 8, 4986–4999 (2019).
Abu-Sbeih, H. et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J. Immunother. Cancer 6, 95 (2018).
Verschuren, E. C. et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin. Gastroenterol. Hepatol. 14, 836–842 (2016).
Karamchandani, D. M. & Chetty, R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective. J. Clin. Pathol. 71, 665–671 (2018).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet. Oncol. 15, 700–712 (2014).
Eggermont, A. M. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).
Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093–2104 (2018).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Kleiner, D. E. & Berman, D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig. Dis. Sci. 57, 2233–2240 (2012).
Delanoy, N. et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 6, e48–e57 (2019). A descriptive observational study describing patients presenting with haematological irAEs induced by PD-1 or PD-L1 inhibitor immunotherapy registered in three French pharmacovigilance databases (REISAMIC, ImmunoTOX and CeReCAI).
Perrinjaquet, C., Desbaillets, N. & Hottinger, A. F. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Curr. Opin. Neurol. 32, 500–510 (2019).
Cuzzubbo, S. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1–8 (2017). A systematic search of literature including 59 clinical trials centred on analysing the incidence and characteristics of neurological irAEs.
Sato, K., Mano, T., Iwata, A. & Toda, T. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. J. Neurooncol. 145, 1–9 (2019).
Dubey, D. et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93, e1093–e1103 (2019).
Bitton, K. et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy. Am. J. Ophthalmol. 202, 109–117 (2019).
Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283–2289 (2006).
Postow, M. A. Managing immune checkpoint-blocking antibody side effects. Am. Soc. Clin. Oncol. Educ. Book 35, 76–83 (2015).
Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N. H. & Hodi, F. S. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2, 1607–1616 (2016).
Ma, K. et al. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front. Pharmacol. 9, 1430 (2018).
Nishino, M. et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin. Cancer Res. 22, 6051–6060 (2016). This paper provides a clear description of the main clinical characteristics, radiographic patterns and treatment course of PD-1 inhibitor-related pneumonitis in patients with advanced cancer.
Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
Cortazar, F. B. et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 90, 638–647 (2016).
Wanchoo, R. et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am. J. Nephrol. 45, 160–169 (2017).
Perazella, M. A. & Shirali, A. C. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int. 97, 62–74 (2020).
Ramos-Casals, M. et al. THU0649 phenotypic clusters of rheumatic/systemic immune-related adverse events induced by cancer immunotherapies (Immunocancer International Registry). Ann. Rheum. Dis. 78, 620–621 (2019).
Manolios, N. & Schrieber, L. Checkpoint inhibitors and arthritis. Ann. Rheum. Dis. 78, e58 (2019).
Richter, M. D. et al. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 71, 468–475 (2019).
Kostine, M. et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer — clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann. Rheum. Dis. 77, 393–398 (2018).
Buder-Bakhaya, K. et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol. Immunother. 67, 175–182 (2018).
Anquetil, C. et al. Immune checkpoint inhibitor-associated myositis. Circulation 138, 743–745 (2018).
Touat, M. et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91, e985–e994 (2018).
Cornejo, C. M., Haun, P., English, J. III & Rosenbach, M. Immune checkpoint inhibitors and the development of granulomatous reactions. J. Am. Acad. Dermatol. 81, 1165–1175 (2019).
Gkiozos, I. et al. Sarcoidosis-like reactions induced by checkpoint inhibitors. J. Thorac. Oncol. 13, 1076–1082 (2018).
Salem, J.-E. et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 19, 1579–1589 (2018).
Daxini, A., Cronin, K. & Sreih, A. G. Vasculitis associated with immune checkpoint inhibitors — a systematic review. Clin. Rheumatol. 37, 2579–2584 (2018).
Ramos-Casals, M. et al. Sicca/Sjögren syndrome triggered by PD-1/PD-L1 checkpoint inhibitors: data from the International Immunocancer Registry (ICIR). Clin. Exp. Rheumatol. 37, 114–122 (2019).
Hodi, F. S. et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 1480–1492 (2018).
Fadel, F., El Karoui, K. & Knebelmann, B. Anti-CTLA4 antibody-induced lupus nephritis. N. Engl. J. Med. 361, 211–212 (2009).
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A. & Suarez-Almazor, M. E. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann. Intern. Med. 168, 121–130 (2018). A complete summary of the evidence on irAEs associated with ICIs in patients with cancer and pre-existing autoimmune disease.
Danlos, F.-X. et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur. J. Cancer 91, 21–29 (2018).
Kostine, M. et al. OP0165 EULAR recommendations for the diagnosis and the management of rheumatic immune-related adverse events due to cancer immunotherapy. Ann. Rheum. Dis. 78, 158 (2019).
Kaur, A. et al. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a single-center experience. Medicine 98, e17348 (2019).
Kahler, K. C. et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol. Immunother. 67, 825–834 (2018).
Tison, A. et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 71, 2100–2111 (2019).
Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234–240 (2016).
Leonardi, G. C. et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J. Clin. Oncol. 36, 1905–1912 (2018).
Gutzmer, R. et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur. J. Cancer 75, 24–32 (2017).
Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017).
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
Mammen, A. L. et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann. Rheum. Dis. 78, 150–152 (2019).
Kobayashi, T. et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J. Endocr. Soc. 2, 241–251 (2018).
Ali, O. H. et al. BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J. Am. Acad. Dermatol. 82, 854–861 (2020).
Sakakida, T. et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies. Clin. Transl. Oncol. https://doi.org/10.1007/s12094-019-02214-8 (2019).
Tahir, S. A. et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl Acad. Sci. USA 116, 22246–22251 (2019).
Young, A., Quandt, Z. & Bluestone, J. A. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol. Res. 6, 1445–1452 (2018).
Haanen, J. B. A. G. et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv264–iv266 (2018).
Min, L. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin. Cancer Res. 21, 749–755 (2015).
Weber, J. et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 15, 5591–5598 (2009).
Torino, F., Corsello, S. M. & Salvatori, R. Endocrinological side-effects of immune checkpoint inhibitors. Curr. Opin. Oncol. 28, 278–287 (2016).
Roberts, J. et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin. Rheumatol. 38, 1513–1519 (2019).
Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176–189 (2013).
Touat, M., Talmasov, D., Ricard, D. & Psimaras, D. Neurological toxicities associated with immune-checkpoint inhibitors. Curr. Opin. Neurol. 30, 659–668 (2017).
Baddley, J. W. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin. Microbiol. Infect. 24, S10–S20 (2018).
Martins, F. et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 20, e54–e64 (2019).
Johnson, D. H. et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J. Immunother. Cancer 6, 103 (2018).
Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428–432 (2019).
Bergqvist, V. et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol. Immunother. 66, 581–592 (2017).
Abu-Sbeih, H. et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J. Immunother. Cancer 6, 142 (2018).
Siakavellas, S. I. & Bamias, G. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease? Curr. Opin. Gastroenterol. 34, 377–383 (2018).
Stroud, C. R. et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J. Oncol. Pharm. Pract. 25, 551–557 (2019).
Williams, T. J. et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 73, 928–933 (2016).
Khan, U., Ali, F., Khurram, M. S., Zaka, A. & Hadid, T. Immunotherapy-associated autoimmune hemolytic anemia. J. Immunother. Cancer 5, 15 (2017).
Sowerby, L., Dewan, A. K., Granter, S., Gandhi, L. & LeBoeuf, N. R. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 153, 603–605 (2017).
Salem, J.-E. et al. Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N. Engl. J. Med. 380, 2377–2379 (2019).
Esfahani, K. et al. Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N. Engl. J. Med. 380, 2375–2376 (2019).
Akiyama, M., Kaneko, Y., Yamaoka, K., Kondo, H. & Takeuchi, T. Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. Rheumatol. Int. 36, 881–889 (2016).
Korzenik, J., Larsen, M. D., Nielsen, J., Kjeldsen, J. & Norgard, B. M. Increased risk of developing Crohn’s disease or ulcerative colitis in 17018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment. Pharmacol. Ther. 50, 289–294 (2019).
Danese, S. & Fiorino, G. Anti-TNF biosimilars in inflammatory bowel disease: searching the proper patient’s profile. Curr. Med. Chem. 26, 280–287 (2019).
Strangfeld, A. et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann. Rheum. Dis. 76, 504–510 (2017).
Redelman-Sidi, G. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin. Microbiol. Infect. 24, S95–S107 (2018).
Andrews, S. & Holden, R. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag. Res. 4, 299–307 (2012).
Del Castillo, M. et al. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis. 63, 1490–1493 (2016).
Franklin, C. et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur. J. Cancer 86, 248–256 (2017).
Kuo, J. R. et al. Severe diarrhea in the setting of immune checkpoint inhibitors. Case Rep. Gastroenterol. 12, 704–708 (2018).
Schwarz, M. et al. Immunosuppression for immune checkpoint-related toxicity can cause Pneumocystis jirovecii pneumonia (PJP) in non-small-cell lung cancer (NSCLC): a report of 2 cases. Clin. Lung Cancer 20, e247–e250 (2019).
Picchi, H. et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin. Microbiol. Infect. 24, 216–218 (2018).
Koksal, A. S. et al. HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma. Ann. Oncol. 28, 3103–3104 (2017).
Pandey, A., Ezemenari, S., Liaukovich, M., Richard, I. & Boris, A. A rare case of pembrolizumab-induced reactivation of hepatitis B. Case Rep. Oncol. Med. 2018, 5985131 (2018).
Uslu, U. et al. Autoimmune colitis and subsequent CMV-induced hepatitis after treatment with ipilimumab. J. Immunother. 38, 212–215 (2015).
Johnson, D. B., Sullivan, R. J. & Menzies, A. M. Immune checkpoint inhibitors in challenging populations. Cancer 123, 1904–1911 (2017).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).
Pollack, M. H. et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann. Oncol. 29, 250–255 (2018).
Santini, F. C. et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol. Res. 6, 1093–1099 (2018).
Simonaggio, A. et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 5, 1310–1317 (2019).
Abu-Sbeih, H. et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J. Clin. Oncol. 37, 2738–2745 (2019).
van Holstein, Y. et al. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging 36, 927–938 (2019).
Hall, E. T. et al. Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care — a systematic review. J. Pain Symptom Manage. 58, 137–156.e1 (2019).
Long, G. V. et al. Effect of nivolumab on health-related quality of life in patients with treatment-naive advanced melanoma: results from the phase III CheckMate 066 study. Ann. Oncol. 27, 1940–1946 (2016).
Lebbe, C. et al. Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial. J. Clin. Oncol. 37, 867–875 (2019).
Schadendorf, D. et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur. J. Cancer 82, 80–91 (2017).
O’Reilly, A. et al. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support. Care Cancer 28, 561–570 (2020).
Rogiers, A. et al. Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J. Oncol. 2019, 5269062 (2019).
Lai-Kwon, J. et al. The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. J. Cancer Surviv. 13, 503–511 (2019).
Joly, F., Castel, H., Tron, L., Lange, M. & Vardy, J. Potential effect of immunotherapy agents on cognitive function in cancer patients. J. Natl Cancer Inst. 112, 123–127 (2020).
Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).
Freeman-Keller, M. et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res. 22, 886–894 (2016).
Teulings, H.-E. et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33, 773–781 (2015).
Khunger, M. et al. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152, 271–281 (2017).
Hamamoto, Y., Shin, N., Hoshino, T. & Kanai, T. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. Future Oncol. 14, 3187–3198 (2018).
Hofmann, L. et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 190–209 (2016).
Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018). One of the largest evaluations of fatal ICI-associated toxic effects performed after a retrospective evaluation of the WHO pharmacovigilance database Vigilyze.
De Velasco, G. et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol. Res. 5, 312–318 (2017).
Al-Kindi, S. G. & Oliveira, G. H. Reporting of immune checkpoint inhibitor-associated myocarditis. Lancet 392, 382–383 (2018).
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391, 933 (2018).
Moreira, A. et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur. J. Cancer 106, 12–23 (2019).
Liewluck, T., Kao, J. C. & Mauermann, M. L. PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies. J. Immunother. 41, 208–211 (2018).
Lisberg, A. et al. Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center. Cancer Immunol. Res. 6, 288–294 (2018).
Powles, T. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol. 3, e172411 (2017).
Sharma, P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 17, 1590–1598 (2016).
Davis, E. J. et al. Hematologic complications of immune checkpoint inhibitors. Oncologist 24, 584–588 (2019).
Davar, D., Wilson, M., Pruckner, C. & Kirkwood, J. M. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep. Oncol. Med. 2015, 737389 (2015).
Cook, M. R. & Kim, C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 5, 1049–1054 (2019).
Tio, M. et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur. J. Cancer 104, 137–144 (2018).
Simons, K. H. et al. T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nat. Rev. Cardiol. 16, 325–343 (2019).
Ward, E. M., Flowers, C. R., Gansler, T., Omer, S. B. & Bednarczyk, R. A. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J. Clin. 67, 398–410 (2017).
Wijn, D. H. et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur. J. Cancer 104, 182–187 (2018).
Naidoo, J. et al. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J. Natl Compr. Canc. Netw. 17, 712–720 (2019).
Scotte, F., Ratta, R. & Beuzeboc, P. Side effects of immunotherapy: a constant challenge for oncologists. Curr. Opin. Oncol. 31, 280–285 (2019).
Kostine, M. et al. Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists? Ann. Rheum. Dis. 78, 860–862 (2019).
Evens, A. et al. A pictorial assay of immunotherapy: complications that internists will see, whether they like it or not. Am. J. Med. 132, 808–815 (2019).
Kantarjian, H. & Yu, P. P. Artificial intelligence, big data, and cancer. JAMA Oncol. 1, 573–574 (2015).
Mekki, A. et al. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. Eur. J. Cancer 119, 44–56 (2019).
Hsiehchen, D., Watters, M. K., Lu, R., Xie, Y. & Gerber, D. E. Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors. JAMA Netw. Open 2, e1911519 (2019).
Pitt, J. M. et al. Fine-tuning cancer immunotherapy: optimizing the gut microbiome. Cancer Res. 76, 4602–4607 (2016).
Wang, Y. et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat. Med. 24, 1804–1808 (2018).
Wang, W. et al. Assessing the viability of transplanted gut microbiota by sequential tagging with D-amino acid-based metabolic probes. Nat. Commun. 10, 1317 (2019).
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
Simon, N. et al. Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight 4, 123281 (2019).
Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47–62 (2018).
Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175–196 (2019).
Francisco, L. M., Sage, P. T. & Sharpe, A. H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219–242 (2010).
Fife, B. T. & Pauken, K. E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann. N. Y. Acad. Sci. 1217, 45–59 (2011).
Wang, X., Teng, F., Kong, L. & Yu, J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco. Targets Ther. 9, 5023–5039 (2016).
Gandini, S., Massi, D. & Mandala, M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 100, 88–98 (2016).
Weber, J. S. et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J. Clin. Oncol. 35, 785–792 (2017).
Horvat, T. Z. et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J. Clin. Oncol. 33, 3193–3198 (2015).
Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872–2878 (2018).
Maher, V. E. et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J. Clin. Oncol. 37, 2730–2737 (2019).
Obradovic, M. M. S. et al. Glucocorticoids promote breast cancer metastasis. Nature 567, 540–544 (2019).
Draghi, A. et al. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int. J. Cancer 145, 1408–1413 (2019).
This work was supported in part by the Memorial Sloan Kettering Cancer Center (MSKCC) NCI core grant P30 CA008748 and the University of Texas NCI core grant P30 CA016672. The authors thank F. Schettini from IDIBAPS/Hospital Clinic (Barcelona, Spain) for his assistance with the manuscript.
M.R.-C. has received compensation for consulting services and/or speaking activities from Bristol-Myers Squibb and Gilead. J.R.B. has received compensation for consulting services and/or speaking activities from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech and Merck. M.K.C. declares institutional research support and employment of a family member by Bristol-Myers Squibb and consulting, advisory or speaking compensation from AstraZeneca/MedImmune, Incyte, Moderna and Merck. O.L. has received compensation for consulting services and/or speaking activities from AstraZeneca, Bristol-Myers Squibb France, Incyte, Janssen and MSD, and received research support from Gilead. X.M. has received compensation for consulting services and/or speaking activities from Bristol-Myers Squibb. A.P. has received compensation for consulting services and/or speaking activities from Amgen, Bristol-Myers Squibb, Daiichi Sankyo, Novartis, Oncolytics Biotech, Pfizer, Puma and Roche, and received research support from Boehringer Ingelheim, Nanostring, Novartis and Roche. M.E.S.-A. has received funding for consulting services from AbbVie, Agile Pharmaceuticals, Amag Pharmaceuticals, Eli Lilly and Pfizer unrelated to this topic. All other authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ramos-Casals, M., Brahmer, J.R., Callahan, M.K. et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6, 38 (2020). https://doi.org/10.1038/s41572-020-0160-6
Biomarker Research (2022)
Pneumatosis cystoides intestinalis associated with etoposide in hematological malignancies: a case report and a literature review
BMC Gastroenterology (2022)
Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors
Nature Biomedical Engineering (2022)
Nature Reviews Rheumatology (2022)
Nature Reviews Clinical Oncology (2022)